Together, our findings indicate that abnormalities in ceramide metabolism are a feature of LBD, constituting a promising source of biomarkers, and that GBA mutations likely accelerate the pathological process occurring in sporadic LBD through endolysosomal deficiency. The gene discussed is GBA1; the disease is hyperinsulinemic hypoglycemia, familial, 4.